Find Oncology Drugs in Phase I/II Clinical Development in FRANCE

Lead Product(s): AsiDNA,Niraparib

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

The REVOCAN ph 1b/2 study, will evaluate the effect of AsiDNAâ„¢ on the acquired resistance to PARP inhibitor niraparib in 2nd line maintenance treatment of relapsed ovarian cancer.

Lead Product(s): PDC lung01

Therapeutic Area: Oncology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Korean Investment Partners

Deal Size: $22.2 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 22, 2020

Details:

Funding will support company’s phase I/II trial with PDC*lung01 candidate in lung cancer.